An interventional study of Liposomal Bupivicaine and Saline Solution (NaCl 0,9%) in Intertrochanteric Fractures, Hip Fractures and Sleep Disturbance, sponsored by Li Xiaoyuan. Completed at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Li Xiaoyuan · Not applicable, Interventional, and Supportive care
Older adults with hip fracture often experience severe pain before and after surgery. This pain can cause anxiety and poor sleep, and may increase the risk of postoperative delirium (sudden confusion after surgery). A fascia iliaca compartment block (FICB) is an injection of numbing medicine near the hip nerves that relieves pain, but standard numbing medicines only last about 8 to 12 hours. Liposomal bupivacaine is a long-acting form of a numbing medicine that may relieve pain for up to 72 hours after a single injection.
This study tests whether giving an ultrasound-guided FICB with liposomal bupivacaine immediately after hospital admission (before surgery) improves sleep quality, reduces anxiety and pain, lowers the need for opioid pain medicines, and reduces postoperative delirium in patients aged 65 to 80 years undergoing surgery for intertrochanteric hip fracture, compared with a placebo (saline) injection. All participants in both groups receive the same standard pain treatment, including scheduled intravenous dexketoprofen and patient-controlled analgesia after surgery.
This is a prospective, randomized, placebo-controlled, double-blind, single-center trial. Eighty patients aged 65-80 years (ASA physical status II-III) scheduled for closed reduction and proximal femoral nail antirotation (PFNA) fixation of a unilateral intertrochanteric femoral fracture under intrathecal anesthesia are randomized 1:1 to two groups.
Immediately after enrollment on admission, the intervention group (Group Z) receives an ultrasound-guided suprainguinal fascia iliaca compartment block (FICB) with liposomal bupivacaine 133 mg diluted to 40 mL with normal saline; the control group (Group D) receives 40 mL of normal saline by the identical technique. The block is performed by a single experienced anesthesiologist using a high-frequency linear probe and an in-plane technique, with the "hill sign" view (subcutaneous tissue, abdominal wall muscles, fascia iliaca, iliacus muscle, and ilium) confirming correct injection between the fascia iliaca and the iliacus muscle. Sensory blockade is assessed 20 minutes after injection by a blinded anesthesiologist using pinprick in the femoral, obturator, and lateral femoral cutaneous nerve territories; results are sealed and not used for clinical decisions until unblinding.
Both groups receive identical multimodal baseline analgesia (intravenous dexketoprofen trometamol 100 mg twice daily until the day of surgery), identical standardized spinal anesthesia (0.75% bupivacaine 1 mL diluted to 3 mL with cerebrospinal fluid at L3-4) with intraoperative dexmedetomidine infusion (0.3 microgram/kg/h), standardized hemodynamic management, and identical postoperative sufentanil-based patient-controlled intravenous analgesia (PCIA; sufentanil 1 microgram/kg in 150 mL, background 2 mL/h, bolus 2 mL, lockout 15 min). Rescue analgesia (intramuscular tramadol 50 mg) is given when resting VAS >= 4 despite PCIA.
Randomization is performed with an online random number generator (Research Randomizer) with allocation concealment using sealed opaque envelopes opened only by the study-drug preparation nurse, who does not participate in block performance, outcome assessment, or data analysis. Participants, the anesthesiologist performing the block, outcome assessors, and the statistician are blinded to group allocation.
The primary outcome is the Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission (the first night after the intervention). Secondary outcomes include LSEQ scores on the night of surgery and the second postoperative night, objective sleep parameters derived from a wrist-worn activity tracker (Fitbit Charge 6), anxiety scores, postoperative pain scores, perioperative sufentanil consumption, rescue analgesia, incidence of postoperative delirium (assessed twice daily on postoperative days 1-3 with the Confusion Assessment Method), time to first ambulation, postoperative length of stay, and adverse events.
The planned sample size of 40 per group provides 80% power (two-sided alpha = 0.05) to detect a between-group difference of approximately 34 points in the primary outcome assuming a pooled standard deviation of 52 points (based on an internal pilot study), allowing for 10% attrition.
848 studies on the registry are indexed under Hip Fractures; 160 are open to participants now.
This study's enrollment of 80 is below the median of 90 across 540 interventional studies indexed under Hip Fractures.
Browse Hip Fractures studies →This is the only study on the registry with Li Xiaoyuan as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ultrasound-guided suprainguinal fascia iliaca compartment block with liposomal bupivacaine 133 mg diluted to 40 mL with normal saline, performed immediately after admission/enrollment.
Drug: Liposomal Bupivicaine
Ultrasound-guided suprainguinal fascia iliaca compartment block with 40 mL of 0.9% normal saline, performed immediately after admission/enrollment by the identical technique.
Drug: Saline Solution (NaCl 0,9%)
1.Arm 1 - Experimental: Liposomal bupivacaine group (Group Z) * Intervention (Drug): Liposomal Bupivacaine * Description: Single ultrasound-guided suprainguinal FICB injection of liposomal bupivacaine 133 mg/10 mL diluted to 40 mL with 0.9% saline, injected between the fascia iliaca and iliacus muscle.
2.Arm 2 - Placebo Comparator: Saline group (Group D) * Intervention (Drug): Normal saline * Description: Single ultrasound-guided suprainguinal FICB injection of 40 mL 0.9% sodium chloride solution (placebo).
Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission
Total LSEQ score (10 items, each scored on a 100-mm visual analogue line; total range 0-1000; higher scores indicate better sleep) for the night of admission, i.e., the first night after the study intervention, assessed the following morning by a blinded assessor.
Time frame: Night of admission (within approximately 24 hours after the intervention)
LSEQ score on the night of surgery
Time frame: Night of the day of surgery
LSEQ score on the second postoperative night
Time frame: Postoperative day 2 (night)
Total sleep time (wristband actigraphy)
Time frame: Objective total sleep time (hours) recorded by a wrist-worn activity tracker (Fitbit Charge 6). Time Frame: Night of admission, night of surgery, and second postoperative night
Deep sleep time (wristband actigraphy)
Time frame: Night of admission, night of surgery, and second postoperative night
Number of nocturnal awakenings (wristband actigraphy)
Time frame: Night of admission, night of surgery, and second postoperative night
Anxiety score (VAS-A)
Time frame: Night of admission, night of surgery, and second postoperative night
Resting pain score (VAS)
Time frame: 6, 24, and 48 hours after surgery
Cumulative sufentanil consumption
Time frame: 0-48 hours after surgery
Number of effective PCIA demands
Time frame: 0-48 hours after surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Sep 2026, 8 months.
Of 225 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's 8 months is below that.
Counting every sponsor, half of 239 studies reached it within 29 months; a quarter within 10 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine